Resistance threatens all our currently available anti-malarial drugs. Triple artemisinin-containing combination anti-malarial treatments (TACTs) combine an artemisinin derivative with two slowly eliminated partner drugs. TACTs are undergoing large-scale trials. If they prove safe, well-tolerated and efficacious then they should be deployed. This is in order to protect and extend the useful therapeutic life of the current generation of anti-malarial drugs, which are so essential for malaria control and elimination.
CITATION STYLE
White, N. J. (2019, October 11). Triple artemisinin-containing combination anti-malarial treatments should be implemented now to delay the emergence of resistance. Malaria Journal. BioMed Central Ltd. https://doi.org/10.1186/s12936-019-2955-z
Mendeley helps you to discover research relevant for your work.